| Chapter title |
Trametinib (GSK1120212)
|
|---|---|
| Chapter number | 7 |
| Book title |
Small Molecules in Oncology
|
| Published in |
Recent results in cancer research Fortschritte der Krebsforschung Progrès dans les recherches sur le cancer, January 2018
|
| DOI | 10.1007/978-3-319-91442-8_7 |
| Pubmed ID | |
| Book ISBNs |
978-3-31-991441-1, 978-3-31-991442-8
|
| Authors |
Robert Zeiser, Hana Andrlová, Frank Meiss, Zeiser, Robert, Andrlová, Hana, Meiss, Frank |
| Abstract |
The mitogen-activated protein kinase (MEK MAPK/ERK kinase) signaling pathways play a critical role in the regulation of diverse cellular activities, including survival, differentiation, proliferation, motility, and angiogenesis. Therefore, MEK inhibition was recognized as a promising target for antineoplastic therapy. Trametinib (GSK1120212), an oral MEK inhibitor which is selective for MEK1 and MEK2, has been approved by the FDA for the treatment of metastatic melanoma in a combination with a BRAF inhibitor. In this overview, preclinical and clinical data for trametinib are presented including mechanisms based on in vitro studies as well as findings from different clinical studies. The future clinical trial in different solid tumor entities will define the therapeutic role of this targeted therapy approach, possibly as a combination with other targeted therapies such as BRAF inhibitors. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 57 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 9 | 16% |
| Student > Bachelor | 5 | 9% |
| Student > Master | 4 | 7% |
| Student > Doctoral Student | 3 | 5% |
| Student > Postgraduate | 3 | 5% |
| Other | 4 | 7% |
| Unknown | 29 | 51% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 11 | 19% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 7% |
| Chemistry | 4 | 7% |
| Medicine and Dentistry | 4 | 7% |
| Business, Management and Accounting | 2 | 4% |
| Other | 4 | 7% |
| Unknown | 28 | 49% |